Therapy Areas: Oncology
Sanofi granted non-exclusive license to Scribe Therapeutics' genome editing technology
27 September 2022 - Molecular engineering company Scribe Therapeutics Inc announced on Tuesday a new research collaboration with French healthcare company Sanofi SA (Euronext Paris: SAN) (NASDAQ: SNY)...
Corbus Pharmaceuticals Holdings, Inc names new director
27 September 2022 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a US-based immunology company, announced on Monday that it has named Anne Altmeyer, PhD, MBA, MPH as its new director.Presentl...
Telix Pharmaceuticals and GenesisCare enrol first patient in TLX591 phase II ProstACT TARGET study
27 September 2022 - Telix Pharmaceuticals Limited (ASX: TLX), an Australian biopharmaceutical company, and GenesisCare, a company that provides integrated cancer care in Australia, announced on Monday...
First Volunteers Vaccinatated at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate
26 September 2022 - - US-based nonprofit scientific research organization IAVI said volunteers at the PREVAIL clinical trial site at Redemption Hospital in Monrovia, Liberia, have been vaccinated with...
Biologics License Application Accepted for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
26 September 2022 - - China-based commercial stage biopharmaceutical company InnoCare Pharma (HKEX: 09969) has received acceptance of the biologics license application for tafasitamab in combination w...
Alpine Immune Sciences to Host R and D Day
26 September 2022 - - US-based clinical-stage immunotherapy company Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will host an R and D Day featuring clinical data presentations on ALPN-303, a potentiall...